Serogroup B meningococcal disease during Hajj: Preparing for the worst scenario
Summary
The Islamic Hajj pilgrimage to Mecca, Saudi Arabia has historically been associated with outbreaks of serogroup A and W135 meningococcal disease. Prevention against meningococcal disease has principally been vaccination with meningococcal polysaccharide vaccines, either in a bivalent serogroup A/C or quadrivalent A/C/Y/W135 form. These interventions have suppressed meningococcal disease since 2002. Countries with large Muslim populations have now started to show a trend of increased serogroup B meningococcal disease, a serogroup for which there is no universal vaccine available. These trends should increase our preparedness to expect a sudden change in the etiology of meningococcal disease during the Hajj.
Keywords: Meningococcal, Hajj, Serogroup B, Vaccine, Pilgrimage
To access this article, please choose from the options below
PII: S1477-8939(09)00120-3
doi:10.1016/j.tmaid.2009.07.001
© 2009 Elsevier Ltd. All rights reserved.
